Approach

Introducing a New Path to Drug Discovery : Bi-XDC technology empowers currently undruggable molecules and targets, transforming them into druggable entities. Designed to tackle substantial unmet medical needs in cancer and beyond, Bi-XDC offers a promising solution for advancing healthcare.

Platforms

Tag-Display

Target Activated lead Generation Display(Tag-Display)is a versatile technology platform for high-throughput discovery and screening of bi-specific ligand system, which can continuously provide the required bi-ligands.



Bi-XDC

CBP has pioneered a breakthrough cellular targeting technology using multi-targeting ligands to effectively deliver desired drug payload to and into the specific cells. 

Bispecific Format

Dual tumor antigen targeting
Retains specificity / affinity
Cover Low Receptor expressions
Broad Indications

Molecular Size / Complexity

Enhanced tissue penetration
Simplified manufacturing process

Safety Profile

Wide therapeutic index
Low immunogenicity profile

World of Bi-XDC

Bi-XDC is a breakthrough molecular-level drug delivery system, where conjugated payload is delivered precisely to specific cells via interaction of two ligands with surface receptors of targeted tumor cells, pioneering a novel therapeutic paradigm in this field. Bi-XDC can deliver various payloads, such as toxin (including tubulin inhibitors, topoisomerase inhibitors), PROTAC, radioisotope, photodynamic therapy, immuno-regulators, NK cell & T cell, etc.
Toxin
Bi-XDC seeks to deliver toxin to cancer cells. These comprise dual ligands targeted to a tumor-specific antigen, a linker, which is selectively cleaved by enzymes upregulated in the tumor microenvironment, and a toxic payload. Bi-XDC is designed to fast enrichment of small-molecule toxins at the tumor cells and clearance in healthy cells and tissues,thereby improving therapeutic window.
Tubulin inhibitor: CBP-1008 CBP-1018
Topoisomerase inhibitor: CBP-1019 CBP-1029 CBP-1039 
PROTAC
Targeted protein degradation molecules can degrade previously “undruggable” target proteins through their catalytic mechanism of action. We combine bi-XDC technology and the catalytic approach of targeted protein degradation by taking advantage of our privileged bi-XDC technology and PROTAC’s degradation property, increasing the efficacy vs. tolerability window.
CBP-8088
Radioisotope

Bi-XDC delivers DNA damaging radiation as the tumor killing payload. A non-cleavable linker is necessary to improve the stability and safety of drug in the circulation. To avoid the potential hazards of systemic exposure, dual ligands using small size antibodies and peptides has a higher advantage due to their small size, fast tumor penetration and systemic clearance.
CBP-1023

Immuno-regulators

Immuno-regulators change immune system, including treatments that increase or decrease immune response, so it works more effectively. They can treat various conditions, including cancer and autoimmune diseases. Bi-XDC simultaneously delivers toxins and immuno-regulators to tumor cells and tissues, exerting synergistic effect and anti-tumor mechanism.

Photodynamic Therapy
Photodynamic therapy is a non-invasive or minimally-invasive treatment which applies photosensitizers to create reactive oxygen species exposed to light trigger to destroy cancer cells. Bi-XDC targets tumor cells to deliver photosensitizers, and uses dual targets and directional illumination to achieve multiple targeting and precise treatment.
CBP-1062
NK cell & T cell

CAR-NK/T cell therapy is a modified form of NK/T cells extracted from the human body, which involves the introduction of genetically engineered chimeric antigen receptors through gene transfection technology. Combining Bi-XDC technology with CAR-NK/T can greatly improve target efficiency, overcome design difficulty, and reduce production costs.

Bi-ligand Discovery Platforms

—— Tag-Display

Target Activated lead Generation Display(Tag-Display)is a versatile technology platform for high-throughput discovery and screening of bi-specific ligand system, which can continuously provide the required bi-ligands.

Tag-Display involves four basic steps to generate bi-specific ligands. The first step, two encoded sub-libraries for ligand A and B are constructed under design and then chemically modified. The second step, sub-library A and B areincubated with receptor A and B for a specific time to allow target activated self-assembly of bi-ligands dynamically. The third step, three to five rounds of biopanning are necessary to enrich and screen specific bi-ligands with high affinity. Finally, unique 2D DNA decoding technology is able to identify the coupled bi-ligands.

Efficient Medicine Platform

——Bi-XDC

CBP has pioneered a breakthrough cellular targeting technology using multi-targeting ligands to effectively deliver desired drug payload to and into the specific cells. 

A Bi-XDC drug molecule consists of four parts: ligand A targeting receptor 1, ligand B targeting receptor 2, payload with therapeutic effectiveness, a linker connecting the ligands with payload and ensuring the payload is released only at desired site.

Toxin

Bi-XDC seeks to deliver toxin to cancer cells. These comprise dual ligands targeted to a tumor-specific antigen, a linker, which is selectively cleaved by enzymes upregulated in the tumor microenvironment, and a toxic payload. Bi-XDC is designed to fast enrichment of small-molecule toxins at the tumor cells and clearance in healthy cells and tissues,thereby improving therapeutic window.

Tubulin inhibitor

CBP-1008 CBP-1018

Topoisomerase inhibitor

CBP-1019 CBP-1029

CBP-1039